InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,967.49
(
1.71%
)
Post# of 158400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Zer0Veritas

Send PM Follow Ignore
Followers 332
Posts 11315
Boards Moderated 1
Alias Born 04/14/2010

Zer0Veritas

Re: agraff04 post# 34476

Saturday, 02/16/2013 12:48:29 AM

Saturday, February 16, 2013 12:48:29 AM

Post# of 158400
you are wrong. BMSN already has clinicals in place all they need is FDA approval for the application they submitted. Even then aplastic anemia is eligible for orphan drug status or even breakthrough status which recent companies have been able to get approval in as little as 4-6 months after application acceptance.

You are using the classic generalization argument which simply can not be applied to biopharm stocks and penny stocks. Do the research on BMSN you will find this is a very different case and disease they are working on.

FOR THE HOTTEST PICKS VISIT TEAM VERITAS!!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up